Tacalcitol
 | |
| Systematic (IUPAC) name | |
|---|---|
| (1S,3R,5Z,7E,24R)-9,10-secocholesta-5,7,10-triene-1,3,24-triol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Topical | |
| Identifiers | |
57333-96-7  | |
| D05AX04 | |
| PubChem | CID 5283734 |
| IUPHAR ligand | 2780 |
| ChemSpider |
4446823  |
| UNII |
C2W72OJ5ZU |
| ChEMBL |
CHEMBL340361 |
| Synonyms | (1α,24R)-1,24-Dihydroxyvitamin D3 |
| Chemical data | |
| Formula | C27H44O3 |
| 416.64 | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic vitamin D3 analog.[1]
Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
Mechanism
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with vitamin D receptors on keratinocytes.
Uses
It is usually prescribed by a general practitioner or dermatologist for the treatment of psoriasis, chronic chapped lips and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion.
It has also been used for vitiligo[2] and Hailey-Hailey disease.[3]
References
- ↑ Fukuoka M, Sakurai K, Ohta T, Kiyoki M, Katayama I (2001). "Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes". Skin Pharmacol. Appl. Skin Physiol. 14 (4): 226–33. doi:10.1159/000056351. PMID 11464105.
- ↑ Leone G, Pacifico A, Iacovelli P, Paro Vidolin A, Picardo M (March 2006). "Tacalcitol and narrow-band phototherapy in patients with vitiligo". Clin. Exp. Dermatol. 31 (2): 200–5. doi:10.1111/j.1365-2230.2005.02037.x. PMID 16487090.
- ↑ Aoki T, Hashimoto H, Koseki S, Hozumi Y, Kondo S (November 1998). "1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro". Br. J. Dermatol. 139 (5): 897–901. doi:10.1046/j.1365-2133.1998.02522.x. PMID 9892963.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||